TargetPrint assesses gene expression levels of the estrogen receptor, progesterone receptor, and HER2 .
Agendia released TargetPrint®, a test that quantitatively determines the gene expression levels of the estrogen receptor, progesterone receptor, and HER2 in breast cancer tumor biopsies.
TargetPrint runs on Agendia’s high-density chip, which received market clearance last month from the FDA
“The test’s results give a precise molecular readout of prognostic parameters for breast cancer and provide physicians and patients with reliable guidance on the most suitable treatment for each individual patient,” says Richard A. Bender, M.D., CMO.
